<?xml version="1.0" encoding="UTF-8"?>
<p>The A/17/turkey/Turkey/05/133 H5N2 candidate vaccine was safety and immunogenic. There were a total of 51 adverse events by systemic organ classes, 35 adverse events were reported from the vaccine group (16 participants), and 16 events were from the placebo group (8 participants). The most frequent adverse events were respiratory/thoracic/mediastinal disorders both in the vaccine group (16 events) and the placebo group (6 events), followed by gastrointestinal disorders in the vaccine group (6 events) and the placebo group (4 events). Among the total of 47 local reactions (24 after 1
 <sup>st</sup> immunization and 23 after 2
 <sup>nd</sup> immunization), 31 were from the vaccine group and 16 were from the placebo group. After the 1
 <sup>st</sup> immunization, the most frequent local reaction in vaccine group was stiffness of the nose (6 events), while placebo group reported only 1 event of the stiffness of the nose after the 1
 <sup>st</sup> immunization. After the 2
 <sup>nd</sup> immunization on day 21, the most frequent local reactions in the vaccine group were stiffness of the nose (6 events) and scratchy throat (4 events).
</p>
